Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VINSUVET is a brand of veterinary recombinant protein products developed and manufactured by the Medsintez Plant (Zavod Medsintez) in Russia. The product line is specifically designed for use in companion animals, such as dogs and cats, and includes several biosimilar formulations of human proteins adapted for veterinary medicine. The brand encompasses multiple distinct products: **VINSUVET Glargine**, a long-acting insulin analogue for the treatment of diabetes mellitus; **VINSUVET Mix 30/70**, a biphasic insulin preparation consisting of 30% soluble insulin and 70% isophane insulin; and **VINSUVET FSH**, a recombinant follicle-stimulating hormone used to manage reproductive disorders and stimulate follicular growth. These products provide high-purity, recombinant alternatives to traditional animal-derived or human-labeled medications for veterinary practitioners.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VINSUVET.